Akèy › Kansè pwostat › Oklahoma
Etid klinik pou Kansè pwostat nan Oklahoma
24 etid pou Kansè pwostat ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Oct 2, 2026 · NCT06931340Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06632977Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- Oklahoma Proton Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 29, 2026 · NCT01492972Protoacoustic Imaging For 3D Mapping
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07832617A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Hightower Clinical, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 22, 2026 · NCT07213674Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- Utica Park Urology, Tulsa
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Sep 14, 2026 · NCT06511141Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Urologic Specialists, Tulsa
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 11, 2026 · NCT06056830Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 10, 2026 · NCT05946213The Vanguard Study: Testing a New Way to Screen for Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 18 a 100 · Gason · Mizajou Aug 26, 2026 · NCT06960798Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Aug 19, 2026 · NCT04423211A Study of DM002 in Patients With Advanced Solid Tumors
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06751329Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Cancer Centers of Southwest Oklahoma Research, Lawton
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Jul 14, 2026 · NCT06592924Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
- University of Oklahoma HSC, Oklahoma City
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Apr 1, 2026 · NCT06651359Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Jan 29, 2026 · NCT05806515Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Jan 22, 2026 · NCT06470243Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT07014618SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Connect2Care: Prostate Cancer Education and Screenings for African American Men
- TSET Health Promotion Research Center, Oklahoma City
Ap rekrite
Laj 45 a 69 · Gason · Mizajou Sep 25, 2025 · NCT07055165Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 11, 2025 · NCT03678025A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- Exelixis Clinical Site #13, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 5, 2025 · NCT05932862Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.